Evidence map›Paper›PMID 42369045›Full record

ArticleiScience2026

Serum SOS1 as a prognostic biomarker and therapeutic target for progressive liver disease.

Peter U Amadi, Govind S Gill, Chiamaka W Amadi, Justice O Osuoha, Prince C Odika, Raj M Patel, Suha J Jarad, Hong-Mei Gu, Moattar Latif, Joy A Amadi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Peter U AmadiDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada.
Govind S GillDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada.
Chiamaka W AmadiDepartment of Biochemistry, Imo State University, Owerri, Nigeria.
Justice O OsuohaSchool of Chemistry, Monash University, Melbourne, VIC, Australia.
Prince C OdikaDepartment of Biology, St. Mary's University, Halifax, NS, Canada.
Raj M PatelDepartment of Biochemistry, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada.
Suha J JaradDepartment of Biochemistry, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada.
Hong-Mei GuDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada.
Moattar LatifDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada.
Joy A AmadiDepartment of Human Nutrition and Dietetics, Imo State University, Owerri, Nigeria.
Celestine N EkweoguDepartment of Medical Biochemistry, Imo State University, Owerri, Nigeria.
Melford U ElenduDepartment of Medical Biochemistry, Imo State University, Owerri, Nigeria.
Emmanuel N AgomuoDepartment of Biochemistry, Imo State University, Owerri, Nigeria.
Alastair O'BrienInstitute for Liver and Digestive Health, University College London, London, UK.
Barbora de CourtenSchool of Health and Biomedical Sciences, RMIT University, Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.
Ralf WeiskirchenInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy, and Clinical Chemistry (IFMPEGKC) at RWTH University Aachen, Aachen, Germany.
Da-Wei ZhangDepartment of Pediatrics, Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the lack of a reliable prognostic biomarker for the serial progression of chronic liver disease, we investigated SOS1 linked to stellate cells-driven liver disease progression. A cohort of 556 participants stratified into F0-F1, F2-F3, F4, and HCC, was followed for up to 36 months, measuring serial SOS1 and comparators, modeling outcome discrimination and trajectories, and validating biologic relevance via SOS1 inhibition in stellate cells and a chronic-injury mouse model. SOS1 increased stepwise with disease stage and correlated with APRI and FIB-4 (

Indexed as

health sciences

Identifiers

PMID42369045
PMCPMC13293661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.